Beijing Konruns Pharmaceutical Co.,Ltd. (SHA:603590)
36.79
+0.41 (1.13%)
May 12, 2026, 3:00 PM CST
SHA:603590 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 332.57 | 189.98 | 230.2 | 345.25 | 599.08 |
Short-Term Investments | - | 53.82 | 183.82 | 0.75 | 10.81 |
Trading Asset Securities | 500.43 | 450.66 | 396.41 | 280.37 | 9.04 |
Cash & Short-Term Investments | 833 | 694.46 | 810.43 | 626.36 | 618.93 |
Cash Growth | 19.95% | -14.31% | 29.39% | 1.20% | -59.49% |
Accounts Receivable | 278.09 | 257.38 | 282.83 | 296.39 | 244.38 |
Other Receivables | 76.07 | 33.84 | 35.56 | 27.73 | 6.31 |
Receivables | 354.16 | 291.22 | 318.39 | 324.13 | 250.69 |
Inventory | 54.47 | 72.38 | 48.47 | 36.99 | 47.02 |
Other Current Assets | 153.9 | 28.48 | 52.67 | 29.23 | 31.19 |
Total Current Assets | 1,396 | 1,087 | 1,230 | 1,017 | 947.83 |
Property, Plant & Equipment | 404.15 | 426.73 | 414.54 | 440.14 | 407.06 |
Long-Term Investments | 1,025 | 1,249 | 984.45 | 927.15 | 695.95 |
Goodwill | - | - | 97.64 | 97.64 | 97.64 |
Other Intangible Assets | 833.37 | 842.67 | 854.64 | 812.75 | 815.17 |
Long-Term Deferred Tax Assets | 21.36 | 27.47 | 32.27 | 1.09 | 8.96 |
Long-Term Deferred Charges | 308 | 234.36 | 150.71 | 120.45 | 82.41 |
Other Long-Term Assets | 107.34 | 53.31 | 16.6 | 8.87 | 316.3 |
Total Assets | 4,095 | 3,920 | 3,781 | 3,425 | 3,371 |
Accounts Payable | 31.2 | 73.57 | 82.97 | 48.47 | 46.74 |
Accrued Expenses | 50.01 | 45.68 | 32.15 | 26.82 | 33.99 |
Short-Term Debt | 253.45 | 140.96 | 96.93 | - | - |
Current Portion of Long-Term Debt | 9.25 | 1.07 | 5.12 | - | - |
Current Portion of Leases | - | 7 | 3.95 | 8.71 | 7.5 |
Current Income Taxes Payable | 11.69 | 4.69 | 0.25 | 34.12 | 15.84 |
Current Unearned Revenue | 5.95 | 6.43 | 6.49 | 2.92 | 1.2 |
Other Current Liabilities | 97.89 | 73.29 | 95.53 | 51.32 | 49.49 |
Total Current Liabilities | 459.45 | 352.68 | 323.39 | 172.36 | 154.77 |
Long-Term Debt | 54.28 | 49.85 | 43.78 | - | - |
Long-Term Leases | 3.17 | 10.8 | - | 3.71 | 11.12 |
Long-Term Unearned Revenue | 41.87 | 40.48 | 23.49 | 28.98 | 29.83 |
Long-Term Deferred Tax Liabilities | 39.74 | 39.72 | 27.78 | 29.62 | 45.02 |
Total Liabilities | 598.51 | 493.52 | 418.44 | 234.68 | 240.74 |
Common Stock | 159.01 | 159.36 | 160 | 160 | 160 |
Additional Paid-In Capital | 948.77 | 944.6 | 955.01 | 992.46 | 985.17 |
Retained Earnings | 2,115 | 2,045 | 2,050 | 1,931 | 1,876 |
Treasury Stock | -32.86 | -35.93 | -78.59 | -124.64 | -124.64 |
Comprehensive Income & Other | 21.14 | 31.8 | -26.5 | -32.8 | -8.11 |
Total Common Equity | 3,211 | 3,144 | 3,060 | 2,926 | 2,889 |
Minority Interest | 285.21 | 281.75 | 302.44 | 264.22 | 241.81 |
Shareholders' Equity | 3,496 | 3,426 | 3,362 | 3,190 | 3,131 |
Total Liabilities & Equity | 4,095 | 3,920 | 3,781 | 3,425 | 3,371 |
Total Debt | 320.16 | 209.67 | 149.78 | 12.42 | 18.62 |
Net Cash (Debt) | 512.84 | 484.79 | 660.65 | 613.94 | 600.31 |
Net Cash Growth | 5.79% | -26.62% | 7.61% | 2.27% | -60.08% |
Net Cash Per Share | 3.21 | 3.10 | 4.22 | 3.93 | 3.81 |
Filing Date Shares Outstanding | 158.63 | 159.22 | 158.98 | 156.49 | 156.49 |
Total Common Shares Outstanding | 158.63 | 158.83 | 158.98 | 156.49 | 156.49 |
Working Capital | 936.08 | 733.86 | 906.57 | 844.35 | 793.06 |
Book Value Per Share | 20.24 | 19.80 | 19.25 | 18.70 | 18.46 |
Tangible Book Value | 2,378 | 2,302 | 2,108 | 2,016 | 1,976 |
Tangible Book Value Per Share | 14.99 | 14.49 | 13.26 | 12.88 | 12.63 |
Buildings | - | 324.61 | 322.64 | 323.38 | 322.3 |
Machinery | - | 126.83 | 125.74 | 126.76 | 114.72 |
Construction In Progress | - | 209.85 | 190.8 | 181.98 | 127.26 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.